炎症性肠病患者停用JAK抑制剂后出现新发湿疹性皮疹
该病例系列描述了8例炎症性肠病患者在停用Janus激酶抑制剂(JAKi)后出现新发湿疹性皮疹,推测为特应性皮炎(AD)。中位发病时间为停药后7天(四分位距2-12天)。2例经活检确诊的AD患者在重新启用JAKi及辅助AD治疗后皮疹消退。提示部分IBD患者可能存在AD潜伏易感性,停药后免疫反弹可能触发。
要点
- IBD患者停用JAKi后中位7天可出现新发AD样皮疹。
- 重新启用JAKi及辅助治疗可使部分活检确诊AD患者皮疹消退。
- 停药后免疫反弹可能是触发AD的潜在机制。
核心结论
- 部分IBD患者停用JAKi后出现新发AD,可能与免疫反弹效应有关。
研究设计与样本
- 病例系列,纳入8例停用JAKi后出现新发AD的IBD患者。
主要发现
- AD发病中位时间为停药后7天(四分位距2-12天)。
- 2例活检确诊AD患者经重新启用JAKi及辅助AD治疗后皮疹消退。
临床怎么用
- IBD患者停用JAKi后需监测新发湿疹性皮疹,警惕AD可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe 8 patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy. METHODS: This case series describes 8 patients with IBD who developed de novo AD after withdrawal of JAKi therapy. RESULTS: Median time to AD onset was 7 days (interquartile range 2-12). Two cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments. DISCUSSION: A subset of patients with IBD may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.
引用
- Yanofsky R, McDonald BD, Nikzad N, et al. New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors. Am J Gastroenterol. 2025. PMID: 40844618. doi:10.14309/ajg.0000000000003742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。